Pharmaceutical Sales: 85%
Diagnostic Sales: 10%
Other Sales: 5%

TOP 3 Markets:

1. Finland: 35%
2. Germany: 20%
3. Sweden: 15%

Orion Oyj generates the majority of its sales from the pharmaceutical industry, accounting for approximately 85% of total revenue. The diagnostics sector contributes about 10%, while the remaining 5% comes from other business areas.

Finland is the largest market for Orion Oyj, followed by Germany and Sweden. These three markets together account for 70% of the company's total revenue. This demonstrates the company's strong presence in the Nordic region as well as in Central Europe.

Production sites of Orion Oyj:

1. Espoo, Finland
2. Turku, Finland
3. Salo, Finland
4. Kuopio, Finland

Orion Oyj is a leading company in the pharmaceutical industry in Finland. The main production facilities are located in Espoo, Turku, Salo, and Kuopio. These sites are strategically distributed in Finland to ensure efficient production and distribution of their pharmaceutical products. Orion Oyj places great emphasis on quality and innovation, which is reflected in their state-of-the-art production plants.

Focus on Research and Development: 15% of revenue (2024)

Expansion into New Markets: Asia and North America

Partnerships and Acquisitions: Targeted acquisitions in the field of oncology

Orion Oyj pursues a growth strategy that heavily emphasizes research and development. In 2024, the company invested approximately 15% of its revenue in this area to develop innovative drugs and strengthen its product pipeline.

Another focus is on geographical expansion, particularly in the Asian and North American markets. These regions offer significant growth opportunities due to the increasing demand for pharmaceutical products.

Additionally, Orion is relying on strategic partnerships and acquisitions, especially in the field of oncology, to solidify its market position and integrate new technologies and products into its portfolio. These measures are intended to secure the company's future growth and enhance its competitiveness.

Main raw materials: Active ingredients, excipients, packaging materials

Countries of origin: Germany, India, China, USA

Orion Oyj, a Finnish pharmaceutical company, imports various raw materials and materials necessary for the production of their pharmaceutical products. This includes in particular active ingredients and excipients sourced from countries such as Germany, India, and China. These countries are known for their strong pharmaceutical industries and the production of chemical raw materials.

In addition, Orion sources packaging materials required for the safe and effective distribution of their products. The USA is also an important trading partner, especially for specialized pharmaceutical components and technologies.

This import strategy enables Orion to produce high-quality products while benefiting from the global advantages of cost efficiency and availability.

Market share in the pharmaceutical industry: 4.5% (2024, estimated) R&D investments: 12% of revenue (2024) Patent portfolio: Over 150 active patents (2024)

Orion Oyj has a significant competitive advantage in the pharmaceutical industry, which is manifested through several factors. The company consistently invests a considerable portion of its revenue in research and development, strengthening its innovation capabilities and promoting the development of new products.

The extensive patent portfolio protects Orion from imitators and secures exclusive market positions for its products. Additionally, the company holds a solid market share and a strong presence in Europe, supported by strategic partnerships and a diversified product range.

In summary, Orion Oyj offers a robust competitive advantage through its R&D investments, patent portfolio, and market strategy, enabling the company to thrive in a dynamic and highly competitive market environment.

Institutional Investor Share: approximately 45% (estimated for 2025) Insider Buys/Sells: No significant transactions in the last quarter (estimated for 2025)

The institutional investor share in Orion Oyj is around 45%, indicating a solid trust from institutional investors in the company. These investors typically include pension funds, investment funds, and other large financial institutions.

Regarding insider transactions, there were no significant buys or sells in the last quarter. This could suggest that the management and other insiders are satisfied with the current company strategy and valuation. Such transactions are often seen as indicators of executives' confidence in the company's future development.

Market share of Orion Oyj: 4.5% (estimated, 2025)

Top competitors and their market shares:

1. Novo Nordisk: 15.2%
2. Roche: 12.8%
3. Sanofi: 11.5%
4. AstraZeneca: 9.3%
5. GlaxoSmithKline (GSK): 8.7%
6. Pfizer: 8.0%
7. Bayer: 6.5%
8. Novartis: 5.9%
9. Merck & Co.: 5.2%
10. Orion Oyj: 4.5%

Orion Oyj has a relatively small market share compared to the major pharmaceutical companies. Orion Oyj's moat is mainly based on its specialization in specific niche areas such as Parkinson's therapy and oncology. This specialization allows the company to maintain a strong position in these segments.

In comparison to larger competitors that have more extensive research and development resources and a broader product portfolio, Orion Oyj's moat is less pronounced. Companies like Novo Nordisk and Roche benefit from a stronger global brand image, extensive patents, and a larger geographic presence, giving them a significant advantage.

Nevertheless, through its focus on specialized therapies and strategic partnerships, Orion Oyj can remain competitive. Success in these niche markets can be seen as a relative moat, albeit limited compared to the broader advantages of larger pharmaceutical companies.

Revenue growth: 8.2% (2024) Research and development investments: 12% of revenue (2024) Market share in oncology: 5% (2024)

Orion Oyj recorded a revenue growth of 8.2% in 2024, attributed to a strong product pipeline and successful market launches. Particularly noteworthy is the oncology sector, where Orion was able to expand its market share to 5%. This demonstrates the company's competitiveness and innovation in a high-growth segment.

The company continues to heavily invest in research and development, at 12% of revenue, indicating a long-term growth strategy. These investments could lead to further breakthroughs and diversification of the product portfolio, enhancing future earnings prospects.

In summary, Orion Oyj demonstrates solid fundamentals and a clear strategic focus on growth areas, making the stock a potentially attractive investment, especially for investors interested in long-term growth opportunities.

Dividend Yield: 3.5% (estimated for 2025)
Dividend History: Continuous payout over the last 10 years

Orion Oyj is known for its stable dividend policy. The company has consistently distributed dividends to its shareholders over the past ten years. The estimated dividend yield for 2025 is around 3.5%, which can be considered solid compared to other companies in the industry.

The reliability of the payout is supported by the company's strong financial position and its ability to generate stable profits. Orion Oyj has proven in the past that it is able to pay dividends even in economically challenging times. Analysts expect the company to continue this practice unless significant negative economic changes occur.